Greetings from the President
The Japanese Society of Clinical Pharmacology and Therapeutics
President: HIROSHI WATANABE
Professor and Chairman
Department of Clinical Pharmacology and Therapeutics
Director Clinical Trial Center
Hamamatsu University School of Medicine
Greetings from the President of the Society
It's a great privilege for me to be appointed as president of the Japanese Society of Clinical Pharmacology and Therapeutics. The Society began as the Clinical Pharmacology Study Group established in 1969. It was formally inaugurated in 1980, and today, after becoming a general incorporated association, it has developed into an organization of more than three thousand members. It is an honor for me to serve this important Society along with such esteemed board members and I am also challenged by the weight of responsibility that this position requires.
Since its inception 45 years ago, the Society has pursued science-based drug therapeutics and worked tirelessly to promote drug development in Japan while emphasizing the importance of the clinical evaluation for new drugs.
During this time, the environment surrounding drug therapy and new drug development has been changing significantly. Through advances in molecular biology and pharmacogenomics, personalized medicine has realized the delivery of drugs to individuals for whom they have been specifically created. Also, as the number of global clinical trials increase, the question has arisen as to what kind of contribution Japan might make to drug development in a world where the understanding of clinical studies (including clinical trials) has changed significantly. Japan's Ministry has recognized the role of National University Hospitals in establishing goals for the future: University hospitals must serve in the training of excellent medical professionals by building attractive, integrated educational programs for postgraduates and undergraduates alike. Additionally, we must always pursue the development of new drugs and medical technology through high quality clinical research.
Given the changes in social demands in recent years, both domestically and abroad, the expectations of our Society have become quite substantial. We must strive to fulfill our social responsibility and meet these expectations. As you well know, clinical pharmacology plays two major roles – that of enabling personalized healthcare via knowledge and information in pharmacokinetics, pharmacodynamics and pharmacogenetics, and that of supporting the development of new drugs and presenting new evidence via clinical trials. Each member of JSCPT shoulders these roles each in their own way. To achieve our goals the Society must tackle numerous challenges such as strengthening our network through meetings even at the local level in order to promote education and information exchange. We must also prioritize strengthening cooperation with other academic and administrative authorities and creating frameworks to better share information and promote the internationalization of The Society etc.
The presence and development of the Society are not meant for the sake of the Society itself but rather to achieve "Deliver better medicine to the patient in need as soon as possible." In the next two years I will make every effort to lead with these goals in mind and would greatly appreciate your support and cooperation.
President of the Japanese Society of Clinical Pharmacology and Therapeutics
(Professor, Clinical Pharmacology and Therapeutics,
Hamamatsu University School of Medicine)